Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda reports positive trial data for multiple myeloma therapy

Takeda reports positive trial data for multiple myeloma therapy

7th December 2015

Takeda has announced positive findings from a phase III clinical trial demonstrating the benefits provided by its multiple myeloma therapy Ninlaro.

Results from the TOURMALINE-MM1 trial have shown that treatment with Ninlaro capsules is effective in extending progression-free survival, with a manageable tolerability profile, in patients with relapsed or refractory multiple myeloma.

The international placebo-controlled clinical trial was designed to evaluate once-weekly oral Ninlaro plus lenalidomide and dexamethasone, compared to placebo plus lenalidomide and dexamethasone.

A separate investigational phase II trial has also been launched evaluating an all-oral combination of the drug plus cyclophosphamide and low-dose dexamethasone in newly-diagnosed multiple myeloma patients.

Dr Andy Plump, Takeda's chief medical and scientific officer, said: "The breadth and depth of the TOURMALINE program allows us to gather important data across a broad range of patients that live with multiple myeloma."

Takeda's drug was was recently approved by the US Food and Drug Administration, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.ADNFCR-8000103-ID-801807521-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.